Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy
Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis
Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation that has had inadequate response to laxatives
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen
Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)
Evidence-based recommendations on tocilizumab (RoActemra) for treating systemic juvenile idiopathic arthritis
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)
Evidence-based recommendations on erlotinib (Tarceva) for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating active relapsing–remitting multiple sclerosis (MS)
Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced (unresectable or metastatic) melanoma
Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion
Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of
Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults
Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema secondary to retinal vein occlusion
Evidence-based recommendations on erlotinib (Tarceva) for treating non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on bivalirudin (Angiox) for treating ST-segment-elevation myocardial infarction (STEMI)
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)
Evidence-based recommendations on aflibercept (Eylea) solution for injection for treating wet age-related macular degeneration
Evidence-recommendations on erythropoiesis-stimulation agents (epoetin alfa, beta, theta and zeta and darbepoetin alfa) for anaemia in people with cancer..
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12
Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer
Evidence-based recommendations on capecitabine (Xeloda) and oxaliplatin (Eloxatin) for adjuvant treatment of stage III (Dukes' C) colon (bowel) cancer
Evidence-based recommendations on the use of inhaler systems (devices) for chronic asthma in children under 5
Evidence-based recommendations on the extraction of wisdom teeth
Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence
Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism to treat people on dialysis who have kidney disease
Evidence-based recommendations on naltrexone (Nalorex) for the management of opioid dependence
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C
Evidence-based recommendations on amantadine (Lysovir, Symmetrel), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza (flu)
Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults
Evidence-based recommendations on laparoscopic surgery for colorectal (bowel) cancer
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia (slow heart rate) due to sick sinus syndrome and/or atrioventricular block
Evidence-based recommendations on imatinib for treating unresectable and/or metastatic gastrointestinal stromal tumours (GIST/soft tissue sarcoma)